Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

Can Trulicity® (dulaglutide) be used in patients with impaired hepatic function?

Use Trulicity with caution in patients with impaired hepatic function. No dose adjustment is needed based on hepatic impairment.


Clinical Pharmacology Study: Impaired Hepatic Function

A phase 1, single dose, clinical pharmacology study in patients with varying hepatic impairment showed no relevant changes in the pharmacokinetics of dulaglutide.1

Compared with participants with normal hepatic function, dulaglutide systemic exposure decreased by

  • 23% in patients with mild hepatic impairment
  • 33% in patients with moderate hepatic impairment, and
  • 21% in patients with severe hepatic impairment.1

The maximum serum concentration (Cmax) was decreased by a similar magnitude.1


1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: 30 July 2021

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request